Brand and Other Names:Ethrane, Compound 347
- Classes: General Anesthetics, Inhalation
Dosing & Uses
Dosage Forms & Strengths
volatile liquid for inhalation
- 250mL per bottle (99.9%)
- Induction: 2-4.5% inspired concentrations produce surgical anesthesia within 7-10 min; administer with oxygen or combination of oxygen/nitrous oxide mixture
- Maintenance: 0.5-3% inspired concentrations maintain surgical anesthesia; if added relaxation is required, supplemental with muscle relaxants; ventilate to maintain carbon dioxide tension in arterial blood between 35-45 mmHg
- 0.5-1% as supplement to other general anesthetics
Vaginal delivery: 0.25-1% provides analgesia equivalent to that produced by 30-60% nitrous oxide
Safety and efficacy not established
Serious - Use Alternative
Significant - Monitor Closely
Frequency Not Defined
Motor activity/seizures (with deep anesthesia or light anesthesia accompanied by hypocapnia)
Liver impairment, including hepatic failure (rare)
Known or suspected genetic susceptibility to malignant hyperthermia
Avoid hyperventilation to minimize possible CNS excitation
Continuous blood pressure monitoring required; lighten administration if excessive BP decrease occurs (unless hypovolemic)
Renal dysfunction is associated with serum fluoride levels >50 micromol/L
Postoperative hepatitis reported
Increased intracranial pressure may occur
May trigger skeletal muscle hypermetabolic state leading to high oxygen demand and malignant hyperthermia
Caution in patients considered more susceptible to cortical stimulation
Decrease dose of neuromuscular blocker if coadministered (longer recovery when coadministered with enflurane compared with halothane or nitrous oxide)
May decrease hepatic, renal, hepatic, and splenic blood flow
Should not be used as a sole agent of induction in patients with ventricular dysfunction
- Inhaled anesthetics associated with rare increases in serum potassium levels that have resulted in cardiac arrhythmias and death in pediatric patients postoperatively
- Patients with latent as well as overt neuromuscular disease, particularly Duchenne muscular dystrophy, appear to be most vulnerable
- Concomitant use of succinylcholine has been associated with most, but not all, of these cases
- Elevated serum creatinine kinase levels and, in some cases, changes in urine consistent with myoglobinuria observed
- Despite similar presentation to malignant hyperthermia, none of affected patients exhibited signs or symptoms of muscle rigidity or hypermetabolic state
- Early and aggressive intervention to treat hyperkalemia and resistant arrhythmias recommended
- Evaluation for latent neuromuscular disease recomended
Pregnancy & Lactation
Pregnancy Category: B
Lactation: Unknown whether distributed in breast milk, caution advised
A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA:Information not available.
Mechanism of Action
Onset of action: 7-10 minutes
Peak Plasma Concentration: Biotransformation results in low serum fluoride levels (average 15 micromol/L); can exceed 50 micromol/L if anesthesia >2 MAC hr
Excretion: Respiratory exhaled gases
Increased incidence of malignant hyperthermia with use of volatile anesthetics or depolarizing neuromuscular blockers in patients with gene mutations in ryanodine receptor (RYR1) or calcium channel alpha (1S)- subunit gene (CACNA1S)
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.
The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.
|1||This drug is available at the lowest co-pay. Most commonly, these are generic drugs.|
|2||This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.|
|3||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.|
|4||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|5||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|6||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|NC||NOT COVERED – Drugs that are not covered by the plan.|
Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
Select a box to add or remove a plan.
Select a class to view formulary status for similar drugs